Virvio
Seattle · Founded 2015
About Virvio
Virvio is a pre-clinical biotherapeutic company developing a broadly-neutralizing peptide capable of both pre- and post- exposure containment of influenza. The drug candidate is being developed as a shelf-stable, single-dose, inhaled product suitable for stockpiling and global pandemic preparedness.
Company Facts
- Founded: 2015
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $209.0K
- Last round: Grant (Feb 2016)
- Website: virvio.com
- Phone: [email protected]
Canonical: https://fsome.com/organization/virvio-8416238 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.